Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05743036 |
TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2023-02-24 |
Location
California, United States
Kansas, United States Texas, United States Australia Germany Hungary Italy Poland Spain |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Terminated
|
Drugs
cetuximab, encorafenib, ZN-c3 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05714553 |
TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase
Phase 1, Phase 2
|
Date Added 2023-02-06 |
Location
United Kingdom
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Terminated
|
Drugs
Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT03970382 |
TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Phase
Phase 1
|
Date Added 2019-05-31 |
Location
California, United States
Illinois, United States New York, United States Tennessee, United States Washington, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Suspended
|
Drugs
IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT06043713 |
TitleAutologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Phase
Phase 1
|
Date Added 2023-09-21 |
Location
Washington, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Suspended
|
Drugs
Bendamustine, Cyclophosphamide, Fludarabine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06412198 |
TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | Phase
Phase 1, Phase 2
|
Date Added 2024-05-14 |
Location
Massachusetts, United States
Texas, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Adagrasib, cemiplimab, cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06455254 |
TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM | Phase
Phase 2
|
Date Added 2024-06-12 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06456515 |
TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC | Phase
Not Applicable
|
Date Added 2024-06-13 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT05865535 |
TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia | Phase
Phase 1
|
Date Added 2023-05-19 |
Location
California, United States
Connecticut, United States Florida, United States Nebraska, United States New Jersey, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06176885 |
TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-12-20 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Camrelizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT06185556 |
TitleCOLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases | Phase
Phase 2
|
Date Added 2023-12-29 |
Location
Netherlands
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
